Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
Enrico Maffini(Istituto di Ematologia di Bologna), Mohamad Mohty(Sorbonne Université), Mutlu Arat(Istanbul Florence Nightingale Hospital), Arnold Ganser(Medizinische Hochschule Hannover), Jordi Esteve(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Panagiotis Kottaridis(University of Oxford), Dietrich W. Beelen(Essen University Hospital), Francesco Lanza(Ospedale "Santa Maria delle Croci" di Ravenna), Myriam Labopin(Sorbonne Université), Ibrahim Yakoub‐Agha(Inserm), Hans Martin(Goethe University Frankfurt), Arnon Nagler(Sheba Medical Center), Rocío Parody Porras(Institut Català d'Oncologia), Eva Wagner(Johannes Gutenberg University Mainz), Jacques‐Olivier Bay(Centre Hospitalier Universitaire de Clermont-Ferrand), Nicolaus Kröger(Universität Hamburg), Keith Wilson(Cardiff University), Jakob Passweg(University Hospital of Basel)
Cited by 20
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k